Belgium – Laboratory reagents – raamovereenkomst vervanging reagentia LC-MS

LC-MS analyses within the clinical biology laboratory currently take place primarily via Laboratory Developed Tests (LDTs), which no longer comply with the IVDR regulation (EU 2017/746). A transition to CE-marked commercial reagents is therefore necessary. This transition coincides with the renewal of the LC-MS instruments and associated validation, prompting a tender to be initiated. A contract duration of 5 years has been chosen to spread the significant switch costs (validation, implementation, training, and documentation) and to ensure operational stability. The additional cost is necessary for regulatory compliance and results in quality improvements (traceability, reproducibility, robustness, and validated documentation).